Delivery Order SPE2DB20D1100-SPE2DB25FD6P0
- Not listed
- The Defense Logistics Agency awarded a $12,962.95 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of SKYRIZI 150 mg/ml pen injections. This is a firm fixed-price contract with an ultimate completion date of July 28, 2025, and was competitively awarded with no set-aside designation. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a comprehensive $999,999,999.00...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $17,112.15 for SKYRIZI 150 mg/mL pen injectors under a firm fixed price, non-competitive contract structure. The award was executed on July 21, 2025, with an ultimate completion date of July 22, 2025, and performance will be conducted at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under a larger indefinite delivery vehicle. This...
- The Defense Logistics Agency awarded a $34,799.93 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for SKYRIZI 150 MG/ML in pen milliliter formulation, with an ultimate completion date of July 28, 2025. This non-set-aside contract represents a pharmaceutical supply delivery executed through competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor within the federal medical supply chain,...
- The Defense Logistics Agency awarded a $11,830.00 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 360 mg/2.4 mL on-body 2.4 mL pharmaceutical product. The contract is a firm fixed price delivery order with an ultimate completion date of August 8, 2025, and was awarded on July 18, 2025. This award represents a non-set-aside, competitively awarded contract and constitutes a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $42,722.77 by the Defense Logistics Agency on July 21, 2025, for the supply of SKYRIZI 150 mg/ml pen milliliter pharmaceutical product. The contract is designated as firm fixed price with no set-aside provision and carries an ultimate completion date of July 22, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued...
- The Defense Logistics Agency awarded a $11,830.00 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 180 mg/1.2 ml on-body injectors on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed price contract represents a competitively awarded, non-set-aside procurement of the pharmaceutical product to support federal medical supply requirements. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- This is a $53,151.89 firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of SKYRIZI 150 MG/ML PENML, a medication, with a completion date of June 12, 2025. This delivery order is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with DLA Troop Support Medical, which provides a comprehensive...
- The Defense Logistics Agency awarded a delivery order valued at $11,830.00 to AmerisourceBergen Drug Corp for SKYRIZI 360 mg/2.4 mL on-body injectors on July 25, 2025. This firm fixed-price delivery order is scheduled for completion by August 15, 2025, with performance occurring at the contractor's facility in Conshohocken, Pennsylvania. The award utilized no set-aside designation and was competitively awarded. SKYRIZI is a biologic medication used to treat autoimmune conditions, and this...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $57,451.17 firm-fixed-price contract is for the supply of SKYRIZI 150 MG/ML PENML, a specialty medication. The order has an ultimate completion date of October 17, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of SKYRIZI 150 MG/ML PENML medication. The $25,676.04 firm fixed price contract has a completion date of June 6, 2025 and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is the prime contractor on this order and holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD6P0Delivery Order
On July 25, 2025, the Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $15,877.77 for SKYRIZI 150 mg/ml pen injections. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of July 28, 2025. The pharmaceutical product will be delivered to the Place of Performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026 that enables the contractor to supply medications and medical supplies to military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, secured this award through open competition without set-aside designation. The company's extensive portfolio of federal contracts with the DLA demonstrates its capability to deliver brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains in support of Defense Health Agency operations, the U.S. Coast Guard, and other government healthcare systems. SKYRIZI is a biologic immunosuppressant used in the treatment of inflammatory skin conditions, representing the type of specialized pharmaceutical commodity the contractor routinely provides through its federal medical supply contracts.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.9k | 7/25/25 |